Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-10.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.4
Industry P/E
--
EV/EBITDA
0.4
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-88.5
Face value
--
Shares outstanding
675,000
CFO
$-351.76 Mln
EBITDA
$-363.71 Mln
Net Profit
$-330.51 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aptevo Therapeutics (APVO)
| -95.2 | -32.7 | -92.1 | -99.0 | -96.7 | -88.4 | -- |
|
BSE Sensex
| 5.3 | 0.4 | 9.2 | 6.6 | 17.1 | 18.9 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Aptevo Therapeutics (APVO)
| -98.5 | -92.2 | -70.5 | -78.5 | 300.0 | -48.5 | -69.8 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aptevo Therapeutics (APVO)
|
4.2 | 2.5 | 0.0 | -23.7 | -- | -- | -- | 0.4 |
| 49.9 | 8,093.9 | 1,208.8 | 131.7 | 13.4 | 6.3 | 61.9 | 3.9 | |
| 128.2 | 8,285.0 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 147.5 | 7,242.1 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 53.0 | 9,911.0 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 40.4 | 11,277.9 | 2,298.9 | 643.6 | 35.4 | 29.2 | 18.9 | 5.3 | |
| 52.8 | 6,644.1 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14.4 | 13.6 | |
| 309.4 | 8,699.8 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.1 | 14.7 | |
| 25.9 | 9,881.3 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 126.6 | 12,599.3 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.4 | 4.9 |
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using... ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. Address: 2401 4th Avenue, Seattle, WA, United States, 98121 Read more
President, CEO & Director
Mr. Marvin L. White
President, CEO & Director
Mr. Marvin L. White
Headquarters
Seattle, WA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Aptevo Therapeutics Inc (APVO) stood at $ 14 Mln as on 31-Mar-25
The share price of Aptevo Therapeutics Inc (APVO) is $4.17 (NASDAQ) as of 20-Jun-2025 16:28 EDT. Aptevo Therapeutics Inc (APVO) has given a return of -96.67% in the last 3 years.
Aptevo Therapeutics Inc (APVO) has a market capitalisation of $ 2 Mln as on 18-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Aptevo Therapeutics Inc (APVO) is 0.37 times as on 18-Jun-2025, a 87% discount to its peers’ median range of 2.78 times.
Since, TTM earnings of Aptevo Therapeutics Inc (APVO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Aptevo Therapeutics Inc (APVO) and enter the required number of quantities and click on buy to purchase the shares of Aptevo Therapeutics Inc (APVO).
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. Address: 2401 4th Avenue, Seattle, WA, United States, 98121
The CEO & director of Mr. Marvin L. White. is Aptevo Therapeutics Inc (APVO), and CFO & Sr. VP is Mr. Marvin L. White.
There is no promoter pledging in Aptevo Therapeutics Inc (APVO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,260
|
|
|
1,128
|
|
|
991
|
|
|
988
|
|
|
870
|
|
|
829
|
|
|
809
|
|
|
742
|
|
|
664
|
| Aptevo Therapeutics Inc. (APVO) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Aptevo Therapeutics Inc (APVO) was $0 Mln.
$-0.96
(
